The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status

Experimental and Molecular Pathology

Volumn 73, Issue 1, 2002, Pages 61-66

  Kaneko, Saori ^a,b   Gerasimova, Tsilya ^a   Butler, William M ^c   Cupples, Tommy E ^c   Guerry, Paul L ^c   Greene, Gwen R ^c   Young, S Robert ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c Palmetto Richland Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CENTROMERE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; NEEDLE BIOPSY; ONCOGENE NEU; TREATMENT PLANNING;

EID: 0036074046     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.2002.2438     Document Type: Article

References (25)

1. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
2. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
3. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
4. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer
5. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
6. Recent progress in the clinical development of docetaxel
7. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
8. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
9. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization
10. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: Direct comparison with companion tissue sections
11. Multicolor fluorescence in situ hybridization techniques
12. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
13. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
14. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
15. Stereotectic breast biopsy is accurate, minimally invasive, and cost effective
16. The neu oncogene: Anerb-B-related gene encoding a 185,000-Mr tumour antigen
17. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
18. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
19. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
20. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
21. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
22. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer
23. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer
24. The role of stereotactic biopsy in assessment of nonpalpable breast lesions
25. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays